This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program CFDA 93.395 "Cancer Treatment Research", provides $738,698 in funding to the Beckman Research Institute of the City of Hope to conduct research on a novel approach to treating relapsed/refractory acute myeloid leukemia (AML) in patients over 60 years old.
The key objectives are to: 1) establish the appropriate dosing and safety profile for the addition of anti-CD38 targeted alpha therapy (TAT) to the conditioning regimen of total marrow irradiation (TMLI) plus fludarabine and melphalan, prior to allogeneic hematopoietic cell transplantation; and 2) conduct preclinical studies in humanized CD38 transgenic mouse models to optimize the CD38-TAT as a single agent for AML treatment. The goal is to develop a novel combination of complementary targeted radiotherapies that can safely intensify treatment and improve outcomes for older AML patients with relapsed/refractory disease. The award period runs from March 2025 through February 2030.
Generated 4/1/25, 1:57 AM